Sawai’s Upsher-Smith Takes Aim At US Corticotropin Opportunity
Collaboration With Peptide Specialist AmbioPharm
Upsher-Smith Laboratories, the US arm of Japan’s Sawai Pharmaceutical, has another challenging project in the pipeline with an agreement to develop and market a follow-on version of Mallinckrodt’s Acthar Gel (corticotropin). The Japanese firm revealed Upsher-Smith’s latest finances as it revealed first-quarter financial results.
You may also be interested in...
Sawai has launched what it says is Japan’s first generic version of Pfizer’s Lyrica pregabalin brand, with other Japanese generics firms waiting in the wings.
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.
Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.